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Abstract Parkinson’s disease patients exhibit progressive
spreading of aggregated α-synuclein in the nervous system.
This slow process follows a specific pattern in an inflamed
tissue environment. Recent research suggests that prion-like
mechanisms contribute to the propagation of α-synuclein
pathology. Little is known about factors that might affect the
prion-like behavior of misfolded α-synuclein. In this review,
we suggest that neuroinflammation plays an important role.
We discuss causes of inflammation in the olfactory bulb and
gastrointestinal tract and how this may promote the initial
misfolding and aggregation of α-synuclein, which might set
in motion events that lead to Parkinson's disease neuropa-
thology. We propose that neuroinflammation promotes the
prion-like behavior of α-synuclein and that novel anti-
inflammatory therapies targeting this mechanism could slow
disease progression.
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Introduction
Age-related neurodegenerative disorders, including Parkin-
son’s disease (PD), are neuropathologically characterized by
accumulation of misfolded proteins and the loss of neurons
along with sustained neuroinflammation. Clinically, PD
patients experience both motor (e.g., bradykinesia, resting
tremor, rigidity, and postural instability) and non-motor
symptoms (e.g., hyposmia, constipation, sleep disturbances,
depression, and dementia). Age is considered the single
greatest risk factor for developing PD with 4–5 % of people
over 85 years developing the disease [1]. In PD, dopamine-
producing neurons in the substantia nigra pars compacta
(SNpc) die and there is a concomitant decrease of dopami-
nergic innervation in the striatum. Furthermore, alpha-
synuclein (α-syn) misfolds and forms intraneuronal aggre-
gates in several brain regions. α-Syn is a 140-amino acid
protein encoded by a single gene located in chromosome 4
[2] and was first described to be present in the nucleus and
presynaptic terminals of normal neurons [3]. In PD and the
related synucleinopathies multiple system atrophy and de-
mentia with Lewy bodies, misfolded and aggregated α-syn
forms intra-cytoplasmic inclusions. In PD, they are located
in neurons and are called Lewy bodies (LB) and Lewy
neurites (LN) [4–6]. The idea that α-syn plays a central role
in PD pathogenesis is supported by the link between three
missense α-syn mutations, i.e., Ala53Thr [7], Ala30Pro [8],
and Glu46Lys [9] and autosomal dominant early-onset PD.
Furthermore, multiplications of the gene cause familial
forms of neurodegenerative disease with parkinsonian
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features [10] and certain SNPs in the α-syn promoter are
associated with increased risk for PD [11]. Recent studies
suggest that prion-like cell-to-cell transfer of possibly mis-
folded α-syn contributes to the spreading of neuropathology
from one brain region to the next [12–17].
Although there is no consensus on the causes of sporadic
PD, neuroinflammation appears to play an important role
(reviewed in [18]). Several questions still remain: how, if at
all, is neuroinflammation linked to α-syn misfolding and
aggregation? For example, does neuroinflammation trigger
α-syn misfolding or does aggregated α-syn cause microglia
activation and neuroinflammation? Furthermore, does neu-
roinflammation promote cell-to-cell transfer of α-syn and
seeding and development of new α-syn aggregates? Alter-
natively, does the inflammatory process delay the prion-like
spread of α-syn? In this review, we will discuss various
aspects that drive pathological alterations of α-syn with a
special focus on how neuroinflammation might affect the
different steps.
Involvement of Immune Pathways in the Brain
of Patients with Parkinson’s Disease
Inflammation is a specialized reaction of the body to harm-
ful agents or insults to tissue. Inflammatory processes in the
nervous system are called "neuroinflammation" and they are
characteristic to most neurodegenerative diseases, including
PD. Classically, inflammation and neuroinflammation in-
volve innate and adaptive immune responses that are regu-
lated by secreted factors (e.g., cytokines, chemokines,
complement proteins, acute phase proteins, reactive oxygen
species (ROS), and arachidonate metabolites; reviewed in
[19, 20]). Interestingly, genetic alterations in several im-
mune function-related genes (e.g., DJ-1, leucine-rich repeat
protein kinase-2 (LRRK2) and HLA-DR) can cause familial
PD or increase the risk of developing PD (all studies and
meta-analyses collected in www.pdgene.org). This points to
a key role for immune pathways in the pathogenetic mech-
anisms of PD which are possibly triggered by aging, oxida-
tive stress, or abnormal forms of α-syn (reviewed in [21]).
Microglia and astrocytes are resident immune cells of the
brain. The expression of specific markers associated with
these cells (typically Iba-1, CD11b, and MHC class II for
microglia, GFAP for astrocytes) increases with severity of
neuroinflammation. Positron emission tomography imaging
studies employing microglia-specific markers point to an
early involvement and cerebral propagation of neuroinflam-
mation in PD [22, 23]. Histological analysis of the substan-
tia nigra in PD patients shows activated microglia [24–26], a
high density of astrocytes [27], and in some cases also
infiltrating T lymphocytes [26, 28]. Furthermore, postmor-
tem PD brains exhibit increased levels of tumor necrosis
factor (TNF) [29] and interleukin (IL)-1 and IL-6 [30]. The
cerebrospinal fluid (CSF) of PD patients differs from that
collected from Alzheimer’s disease (AD) patients, other
neurodegenerative disorders or healthy individuals [31].
The CSF levels of transforming growth factor β1 and 2
(TGFβ1 and TGFβ2) [32] and ratios between amyloid-β
(Aβ) 42 with fractalkine/CX3CL1 [33], as well as levels of
complement factors C3 and fH [34], are all altered in PD.
Whether the clinical findings should be taken as evidence
that neuroinflammation directly contributes to neurodegen-
eration in PD is not clear. The secreted factors and activated
immune cells are not just potentially neurotoxic, but can
also exert neuroprotective effects in neurodegenerative dis-
orders (reviewed in [35, 36]).
In summary, signs of neuroinflammation and genetic
links between PD and immune function point to a possible
role of immune pathways in PD. Whether inflammation is
beneficial or detrimental in this context remains unclear and
we think it is pertinent to ask the question what role inflam-
mation could specifically play in propagation of synuclein-
opathy in PD.
Recent Updates About the Link Between α-Synuclein
Aggregation and the Effect of Inflammation
It has been hypothesized that inflammation triggers, or at
least contributes to, the development of α-syn pathology
[12]. Indeed, in cellular assays, misfolded α-syn species can
trigger activation of microglia [37–42], one of the hallmarks
of the neuroinflammatory process. Although a specific
receptor for α-syn binding to microglia is still unknown,
these cells can take up extracellular α-syn [43, 44] that in
turn triggers the release of soluble immune modulators. The
vulnerability of dopaminergic neurons to inflammation has
also been linked to α-syn, as genetic ablation of α-syn in
animal models decreases the sensitivity of these cells to
inflammatory challenges [45]. Factors released from activat-
ed microglia can further enhance oxidative stress, protein
misfolding, and aggregation, creating a positive feedback
loop promoting degeneration of dopaminergic cells [46, 47].
Together, it remains unclear whether α-syn aggregation is a
cause or consequence of inflammation.
Approximately 90 % of α-syn found in LBs is constitu-
tively phosphorylated at serine 87 (S87-P) and serine 129
(S129-P). By contrast, less than 5 % of α-syn is phosphor-
ylated at serine 129 in healthy human brain [48–50]. Phos-
phorylation of α-syn in neuronal cell lines has been linked
to detrimental activation of microglia in mixed cell culture
systems [51], but whether phosphorylation of α-syn induces
inflammation or vice versa is not fully understood. Further-
more, the precise roles of phosphorylation or other post-trans-
lational modifications ofα-syn for neurotoxicity, formation of
562 Mol Neurobiol (2013) 47:561–574
aggregates, and activation of microglia are not clear, with
different studies reporting conflicting results [52–55].
Nitrated forms of α-syn have previously been suggested
to be crucial to the pathogenesis of synucleinopathies [56]
and nitrated α-syn can trigger inflammation and microglia
activation [57, 58]. One study has shown that nitrated α-syn
may be able to recruit peripheral leukocytes in cervical
lymph nodes in a toxin-based (systemic injections of 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine, (MPTP))
mouse model of PD. The same study also shows that adop-
tive transfer of T cells from syngeneic mice immunized with
nitrated α-syn worsens dopaminergic neuron loss after
MPTP treatment of recipient mice [57]. This indicates that
certain adaptive immune mechanisms could play a role in
PD pathobiology.
A recent study suggests that α-syn may be modified by
inflammation caused by expression of human wild-type or
mutant P301L Tau [59]. Both forms of Tau cause micro-
glial changes and increase IL-6 and TNF-α levels while
also increasing the levels of endogenous α-syn and
S129-P α-syn.
Inflammation and aggregation of α-syn are dynamically
interlinked and this interaction probably plays a key role in
the pathogenesis of PD. As discussed in this review, there is
increasing evidence that α-syn aggregation may be initiated
by a seeding mechanism that could spread throughout neu-
rons in a prion-like fashion possibly involving other amy-
loidogenic proteins. For example, fragments of α-syn are
commonly found in Aβ plaques in the brain of AD patients
[60], and certain rare mutations leading to familial forms of
AD have been associated with LB pathology as well [61,
62]. Aggregation of α-syn and Aβ can trigger neuroinflam-
mation, e.g., it activates microglia (for reviews see [63, 64]).
Oxidative stress produced by neuroinflammation is reported
to be a cellular consequence of α-syn aggregation, and
excessive levels of free ROS can trigger more inflammation
and α-syn aggregation [65–67]. This vicious feed-forward
loop of aggregation-induced neuroinflammation that in turn
causes more aggregation may be a central mechanism in the
pathogenesis of PD and other proteinopathies of the brain.
The NAD-dependent deacetylase, sirtuin 1 (SIRT1), has
been recently identified as a possible regulator of α-syn
aggregation. Sirtuins are known to have anti-aging effects
in nematodes and it is suggested that this family of enzymes
may also play an important role in the regulation of inflam-
mation (reviewed in depth by Galli et al. [68]). Recently, it
was demonstrated that overexpression of SIRT1 in A53T
α-syn transgenic mice increases their lifespan and reduces
α-syn aggregation, and conversely, knocking-out SIRT1 has
the opposite effect [69]. The underlying mechanism has
been suggested to be lack of SIRT1-regulated activation of
molecular chaperons, which leads to aggregation of
α-syn. Thus, sirtuins affect both α-syn aggregation and
inflammation and could provide a molecular link be-
tween these two processes in PD.
The development and maintenance of dopaminergic neu-
rons is regulated by the orphan receptor Nurr1 [70]. In addition
to its role in neurons, loss of Nurr1 also disinhibits the NF-kB
signaling cascade in astrocytes and microglia leading to in-
creased secretion of neurotoxic mediators by these cells there-
by promoting the loss of dopaminergic neurons in a mouse
model of PD [71]. Rare mutations in Nurr1 have been associ-
ated with a late-onset familial form of PD, which presents with
reduced expression of Nurr1 in somatic cells including periph-
eral immune cells [72]. This link between Nurr1, inflamma-
tion, and PD phenotype is intriguing, but it remains to be
shown whether it is relevant to α-syn aggregation.
Spread of Synucleinopathy and Progression
of Parkinson’s Disease
The extent of α-syn pathology in the brain is believed to
correlate to neurological disease stage [73]. Thus, just as the
progression of symptoms tends to follow a predictable pat-
tern, e.g., with certain non-motor symptoms preceding the
onset of motor dysfunction, the progression of neuropatho-
logical changes are believed to follow a highly replicable
pattern. Postulated by Braak and colleagues, this progres-
sion is divided into six stages in PD, starting first with the
simultaneous appearance of α-syn aggregates in anterior
olfactory structures and the vagal nerve. Thereafter, the
pathology spreads rostrally, indicated by LNs and to some
extent LBs. During stage 2, the pathology manifests itself in
the caudal raphe nucleus, in the gigantocellular reticular
nucleus, and in the coeruleus–subcoeruleus complex. It is
not until stage 3 where it appears in the substantia nigra. At
stage 4, lesions are detected in proencephalic regions and
finally reach areas of neocortex and prefrontal cortex at the
last stages [74]. This progressive pattern of appearance of α-
syn aggregates in the brain suggests two possible routes for
the spread of synucleinopathy into the brain following long
and unmyelinated axonal projections, with a retrograde or
anterograde progression [75]: first, the gastrointestinal route
from the enteric nervous system (ENS) to the central ner-
vous system (CNS) via dorsal motor neurons of the vagus
(DMV) and the intermediolateral nucleus of the spinal cord
[76–78]; and second, the olfactory route, from the olfactory
bulb to the midbrain via other olfactory areas and the limbic
system [79].
Several groups have debated the validity of the notion of
progression of synucleinopathy and report a broad range of
roughly 50–80 % of cases concurring with Braak’s staging
[80–82] or concluding that it can be readily applied to
most subjects [83]. In addition, other clinical studies on
metabolic, structural, and functional data revealed that
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neuronal populations are differentially vulnerable to
α-syn pathology and hence dysfunction is not in accor-
dance to the proposed staging system [84]. Despite the
controversy about the interpretation of neuropathology
linked to clinical symptoms, these [80–82] and other
studies [85–87] have led to the proposal of a unified
staging system for all Lewy body disorders [88].
Interestingly, an estimated proportion of 90 % of PD
patients exhibit olfactory deficits [89–91]. Several studies
detected olfactory deficits early in the course of the disease,
before the appearance of motor symptoms (for review, see
[92]). Olfactory disturbances occur both in familial and
sporadic forms of PD [90]. Histological studies in PD have
also revealed a high degree of degeneration of olfactory
cells, especially in the anterior olfactory nucleus (AON),
which has been correlated to disease duration and LB load
in the AON and olfactory bulb (OB) [90]. Thus, it has been
proposed that PD might be primarily a disorder of olfaction
[93] and that the olfactory pathways should be of high
interest to study early PD stages.
Other histological studies in pre-symptomatic subjects,
who go on to develop PD later in life, or PD patients with
colonic bacterial infection, demonstrate pathological changes
in the ENS that are associated with premotor symptoms
involving the gastrointestinal (GI) tract and aggregation of
α-syn in the ENS [94–97]. Indeed, the majority of PD
patients display accumulation of pathology-related phosphor-
ylated α-syn in enteric neurons [98]. In line with these find-
ings, the DMV connecting the ENS to the CNS has long been
known to be severely affected in PD, potentially influencing
GI functions [74]. GI-related non-motor symptoms therefore
might represent a prodromal stage of PD.
Together, these data suggest that olfactory and enteric
regions might be the starting points of the disease that
spreads then to the CNS. Based on this idea, Hawkes et al.
proposed a dual-hit hypothesis: a neurotropic pathogen
could attack the nervous system from two routes—anterog-
radely through olfactory tracts and retrogradely through the
vagal nerve—and this pathogen could enter the brain
through the olfactory and enteric epithelium [79, 99]. Apart
from targeting neurons directly, it is quite possible that a
pathogen triggers local inflammatory processes, which
could initiate synucleinopathy in olfactory and enteric
regions leading to a progression of pathology. In the follow-
ing sections, we describe how inflammation in the olfactory
system and in the GI tract might be triggers that start the
process of α-syn aggregation.
A Possible Role for Neuroinflammation in the Olfactory
Bulb as a Trigger for PD
According to histological studies of PD patients' brains, α-
syn abnormalities observed in anterior olfactory structures at
Braak’s stage 1 are restricted to the AON and OB [74, 100].
More recent studies have demonstrated that after this step,
the pathology spreads slowly into other olfactory regions
like the piriform, periamygdaloid and entorhinal cortices,
and the olfactory tubercle, without any progression in non-
olfactory cortical areas [79].
Post-mortem studies investigating neuroinflammation in
PD patients' brains have focused on midbrain structures.
More extensive studies reported activated microglia also in
the hippocampus and the temporal and entorhinal cortices
[24]. Despite the involvement of olfactory regions in PD and
the importance of neuroinflammation in PD, only one study
has focused on the OB and demonstrated microgliosis in the
OB of PD patients [101]. Due to its proximity to the olfac-
tory epithelium and connections with the periphery, the
olfactory system is very sensitive to exogenous pathogens,
which might trigger local inflammation.
Sensibility of the Olfactory Epithelium and Olfactory Bulb
to Inflammation
The olfactory epithelium is the first point of contact with the
external environment. Mucocillaries of the olfactory epithe-
lium act as a partial barrier against exogenous particles in
the air [102, 103], but do not provide complete protection
(for review see [104]). In humans, the thickness of the
olfactory epithelium declines during aging [105] and there-
by it might also become more permeable to particles and
pathogens, increasing the risk of brain infections.
The organization of the human and rodent olfactory sys-
tems is similar [106] despite olfactory functions being less
well developed in humans. In both species, the olfactory
epithelium neurons, in contact with the external environment,
project their axons into the glomerular layer of the OB, where
they contact mitral cells, the relay cells of olfactory informa-
tion. In rodents, these two types of cells have been shown to
constitute a route for pathogen entry into the brain [104].
Further, in rodents, the OB contains a very dense popu-
lation of microglial cells compared to other structures [107,
108], especially in the glomerular layer. A possible role of
microglia in the OB is to phagocytose cellular debris [109]
resulting from the high turnover of olfactory receptor neu-
rons in the olfactory epithelium. Moreover, the microglia
may also phagocytose OB interneurons [110] which are
replaced throughout life in rodents, as well as possibly in
humans, by adult neurogenesis [111–113]. Finally, OB
microglia might also function as a sensor and barrier to
exogenous particles and pathogens and could be involved
in modulation and potentiation of neuroinflammation and
associated disease [114, 115].
Among exogenous particles that can enter the OB, toxins
(for review, see [116]), viruses, and particles (ultra-thin
particles <100 nm, nanoparticles and microparticles) [99,
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115, 117–121] have been widely studied. Studies in animal
models have demonstrated that pathogens can be either
blocked in the glomerular layer of the OB or spread though
the axons of mitral cells to higher olfactory structures,
such as the olfactory tubercle, amygdala, and olfactory
cortex [114, 115].
Viruses Causing Inflammation in Olfactory Structures
The idea of a viral origin of PD was initially based on the
observation that people born during the influenza pandemic
1918–1919 exhibit increased risk of developing parkinson-
ism, or so called post-encephalitic PD [122]. Viral infections
during childhood have also been generally associated with
higher likelihood of developing PD [123]. Moreover, dis-
eases like asthma and seasonal and allergic rhinitis might be
associated with PD [124], suggesting that chronic rhinitis,
i.e., rhinitis-related inflammation, might promote the entry
of neurotropic pathogens via the olfactory route [79]. Inter-
estingly, influenza A virus has been detected in the SNpc of
PD brains [125], and the interferon-induced protein MxA,
which plays a role in defense against influenza virus, is
associated with LBs [126].
The infection by neurotropic viruses through the olfacto-
ry route has been widely studied in experimental animals.
Rodent studies demonstrate that various types of viruses
entering via the olfactory epithelium can infect different cell
types in the OB, leading to dysfunction in olfactory circuits,
and to the activation of glial cells located in the outer layers
of the OB [114, 117, 119, 127–131]. Depending on the viral
dose [115], an immune reaction involving type I interferons
(e.g., IFN-α and IFN-β) can sometimes block the propaga-
tion of the virus from the OB to other brain regions [132],
but the immune reaction can also induce widespread inflam-
mation. The effects of influenza virus infection on olfactory
regions have been well described in rodents [117, 128, 133].
Shortly after infusion of a mouse-adapted human influenza
virus in the nasal cavity of mice, the viral antigen is found in
the OB (and more precisely in glial cells), but not in other
brain regions. Production of cytokines, such as IL-1β and
TNF-α, increased considerably at the onset of disease. The
neuronal release of TNF-α and IL-1β was also increased in
other brain regions, including those directly connected with
the OB (piriform cortex, olfactory tubercle, central amygdala)
and others, such as the hypothalamus. Hence, local infection
in the OB can induce inflammatory signals in distant brain
regions and can trigger global neuroinflammation.
As mentioned above, activated microglia can phagocy-
tose pathogens and unwanted cells [134] acquire an antigen-
presenting cell phenotype and contribute to the recruitment
of T cells [135]. ROS and cytokines produced by microglia
disrupt the blood brain barrier (BBB) [136, 137], and the
effect of these inflammatory mediators is more pronounced
in the olfactory epithelium and OB where the BBB already
is more permeable than the BBB of other structures
[138–141]. Recently, the effect of TNF-α on BBB perme-
ability was shown to favor CNS infection by the West Nile
virus in mice [142]. Thus, neuroinflammation in the OB
might increase BBB permeability, facilitating the penetra-
tion of exogenous pathogens and triggering microgliosis and
leukocyte invasion into the OB, sparking off a vicious circle
of inflammation. Possibly, a similar mechanism plays a role
in humans, after a neurotropic virus infection entering
through the nose.
Recently, Jang and colleagues [143] studied the conse-
quences of H5N1 viral infection in C57Bl/6 mice by intra-
nasal inoculation. The H5N1 avian influenza virus spread
from the periphery to the CNS (via cranial nerves) and was
found in neurons and astrocytes in the solitary nucleus,
locus coeruleus, and in periglomerular and mitral cells of
the OB. Twenty-one days post inoculation, the virus was no
longer found in the brain, but the immune response persisted
at least 2 months. Importantly, this study was the first to
demonstrate the effect of viral infection on α-syn aggrega-
tion. An increase in cellular and secreted phosphorylated
α-syn (pSer129) was observed in the OB, locus coeruleus,
hippocampus, and brainstem. Moreover, aggregated α-syn
was found in the hippocampus, cortex, and brainstem along
with a loss of dopaminergic neurons in SNpc [143]. Taken
together, these data point to the possibility that viral infec-
tion, maybe through inflammatory processes, can increase
α-syn phosphorylation and induce/increase aggregation of
α-syn in the brain.
Micro- and Nanoparticles Trigger Oxidative Stress
and Inflammation in the OB
Certain metal particles might also be involved in PD, for
example, LBs in the brain of PD patients have a high content
of aluminum [144], or an enhanced risk to develop PD has
been reported for subjects on a diet containing high quanti-
ties of iron [145]. Several studies have demonstrated that
various types of particles (gold, 13C, manganese oxide,
titanium dioxide, ferric oxide) can be inhaled, deposited on
olfactory epithelium, tracheobronchial epithelium, and in
lung alveoli in humans and mice (for review, see [121,
146]). Some particles then reach the CNS through olfactory
epithelium and OB [120, 147–151] and may trigger
inflammatory processes in the olfactory circuits. For exam-
ple, in mice, an intranasal administration of Fe2O3 induces
microglial proliferation, activation, and recruitment in the
OB. In vitro, exposure to Fe2O3 leads to the release of ROS
and NO by a microglia cell line that at the same time
increases their proliferation [151]. Thus, chronic exposure
to air particles, particularly in a polluted environment, could
induce a chronic state of inflammation in olfactory and brain
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structures (for an extensive review on the involvement of
viruses, particles, and pesticides in PD, see [152]).
Inflammation Process in the Olfactory Bulb: Local
Consequences
Peripheral injection of lipopolysaccharide (LPS) is a widely
used, but not very well understood, method to induce distant
immune reactions in the rodent brain. Mori et al. and Ota et
al. focused on olfactory regions and showed in mice a
significant loss of cells in the OB and an increase in
TNF-α and IκBα expression after peripheral LPS injection
[153, 154]. Additionally, LPS administration increased ex-
pression of TNF receptors 1 and 2, and caspase 8 gene
[154], as well as enhanced Fas expression [153]. Two other
studies showed that TNF-α itself has deleterious effects
on olfactory cells, causing dysfunction of olfactory neu-
rons [155] and inhibiting regeneration of olfactory mu-
cosa [156]. Moreover, when local inflammation in the
OB after nasal instillation of a mycotoxin is coupled to
a peripheral LPS injection, the expression of immune-
stimulating genes is dramatically increased in the olfac-
tory mucosa and the OB. This suggests that the effects
of peripheral LPS could magnify apoptosis and inflam-
mation in the olfactory epithelium and OB [118].
In summary, local inflammatory processes can lead to
neuronal death and olfactory neuron dysfunction, which
may translate into early olfactory impairments occurring
in early PD. Thus, exposure to viruses and micro/nano-
particles during our lifetime may initiate chronic inflam-
mation through the olfactory network, induce aggregation
of α-syn, and cause damage and dysfunctions that
accumulate over time. This may enhance early synuclein-
opathy in OB and contribute to PD initiation and pro-
gression (see Fig. 1).
Neuroinflammation May Promote Progression
of Synucleinopathy from the Gastrointestinal
Tract to the CNS
A growing body of evidence suggests that early on in PD,
the peripheral nervous system and organs other than the
brain are affected by neuropathological and neuroinflamma-
tory events. Pathomechanisms in the ENS have raised inter-
est in PD research due to distinct non-motor symptoms, such
Fig. 1 Possible initiation
mechanism and spreading of
synucleinopathy from the
olfactory bulb to the brain.
Pathogens or particles entering
the olfactory epithelium spread
to the olfactory bulb (OB)
through axons of olfactory
neurons. The pathogens induce
an inflammatory response and
oxidative stress in the OB and
damage that accumulates
overtime and induces α-syn
misfolding and aggregation. α-
Syn then transfers to
interconnected regions via
prion-like mechanisms and rea-
ches the midbrain. General in-
flammation could promote α-
syn accumulation and spread
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as dysphagia, constipation, and gastroesophageal reflux,
experienced by PD patients [95, 157–161] and, interest-
ingly, by certain elderly healthy individuals with no his-
tory of PD [96, 162–164]. Careful histological studies by
Braak and colleagues support the hypothesis that accumu-
lation of α-syn in the ENS could occur 20 years before the
onset of degenerative changes in the CNS and associated
motor symptoms [76, 94, 158, 164, 165]. The spread from
the ENS to the CNS was proposed to occur via the DMV
and the intermediolateral nucleus of the spinal cord [76,
166, 167]. Very little is known about the mechanisms that
may promote this propagation. For example, a prion-like
cell-to-cell progression along nerve bundles of the vagus
nerve and spinal cord has been suggested [168, 169],
which, similar to prion disorder, could involve immune
pathways as well [170] (Fig. 2). This finds some clinical
support in a study of patients with early stage diagnosed
PD, where α-syn staining in the ENS correlated with com-
promised intestinal barrier integrity. Possible drivers of the
observed pathology may have been bacterial and environ-
mental toxins, resulting in increased oxidative stress most
likely produced by macrophages in the luminal wall [97].
Yet in another study, patients with prolonged inflammation
due to chronic inflammatory bowel disease did not display
colonic synucleinopathy [171]. These findings in human
patients indicate that acute local immune effects and
certain forms of chronic intragastric inflammation may
contribute differently to synucleinopathy in the GI.
In order to model some of the putative mechanisms in
vivo and to validate clinical observations, appropriate rodent
models reflecting the symptoms found in possible early
stage diagnosed PD were studied [172]. Some transgenic
mice expressing mutant human α-syn encoded on artificial
chromosomes reveal early aggregates of α-syn in the ENS
and display motor deficits prior to detectable pathology in
the CNS [172, 173]. In rats, intragastric injection of a
selective proteasome inhibitor induced α-syn aggregation
in DMV [174]. In other studies, chronic intragastric admin-
istration of the mitochondrial toxin rotenone to rats was
reported to induce a progressive accumulation of endoge-
nous α-syn starting in the ENS and reaching the brain along
the vagal and spinal cord nerve connections to the substantia
nigra [175]. Neuropathological changes in the toxicity-
induced PD rat models were accompanied by local neuro-
inflammation. It can be assumed that the resulting tissue
destruction and rotenone directly triggered a local immune
activation and together this may have propagated the
pathology from the GI system to the brain.
In support of a direct link between PD and gut immune
status, it was found that the gene LRRK2, which is the major
genetic cause for familial PD [176–180], is also located in a
risk region for Crohn’s disease [181], an autoimmune-
mediated chronic inflammatory bowel disease. In the brain,
neuronal overexpression of LRRK2 accelerated the develop-
ment of neuropathology in A53T α-syn transgenic mice,
whereas its ablation suppresses neuronal aggregation and
cytotoxicity of α-syn [182]. In the peripheral immune system,
LRRK2 is upregulated in macrophages under inflammatory
conditions which promotes the production of ROS, phagocy-
tosis, and killing of bacteria [183]. The link between genetic
risk for PD and GI immune mechanisms for LRRK2 is
intriguing and warrants further studies to identify possible
associations with progression of α-syn aggregation from the
ENS to the brain.
Before doing so, a better understanding of the GI immune
system is required. The intestines, and in particular the
Fig. 2 Possible spreading of synucleinopathy from the enteric nervous
system to the brain. Macrophages in the lamina propria become reac-
tive upon natural (e.g., bacteria, viruses, etc.) or induced (toxins)
immune challenges. These cells react with secretion of inflammatory
mediators (cytokines, chemokines, ROS, etc.), which can harm the
surrounding tissue and may induce accumulation of α-syn in enteric
nerves. This could alter gut activity, which early on may be observable
by abnormal intestinal motility and constipation. Aggregated α-syn
may be released by damaged nerve cells, which may further activate
local macrophages. Cell-to-cell transmission could further contribute to
the progression of synucleinopathy, which would eventually propagate
from the enteric nervous system into the SNpc via nuclei in vagus and
spinal cord
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subepithelial lamina propria, contain the largest pool of
tissue macrophages in humans. Thereby, the intestines share
physiological similarities with the immune system of the
olfactory epithelium. Macrophages in both locations dem-
onstrate a two-edged sword: on one hand, they maintain
tissue homeostasis by active phagocytosis of invading
pathogens (e.g., bacteria, viruses) in the absence of exces-
sive activation of other immune pathways [108, 166, 184];
on the other hand, they bear the potential to release an
arsenal of detrimental cytokines, chemokines, and ROS
[179, 180]. Thus, depending on the circumstances, GI mac-
rophages have the potential to harm the surrounding tissue
and may play a role in promoting the accumulation of α-syn
in enteric nerves, leading to altered gut motility and consti-
pation and, in later stages, to propagation of the pathology to
the brain. If this indeed constitutes an etiological trigger in
PD, then it could be relevant for developing earlier treat-
ments and diagnosis of the disease.
Mechanisms of Cell-to-Cell Transfer
Post-mortem studies on PD patients who had received intra-
striatal grafts of embryonic dopaminergic neurons over
10 years prior to death showed that some of the grafted
neurons exhibit LBs and LNs cells [14, 16, 17, 185]. These
findings stimulated the hypothesis that misfolded α-syn
transferred directly from host brain cells to the grafted
neurons. In support of this hypothesis, experiments per-
formed in vitro [186, 187] and in vivo [13, 15, 188] have
demonstrated that α-syn indeed can transfer between cells
(Fig. 3) in a prion-like fashion. This is of direct relevance for
how α-syn pathology might spread throughout the brain
during the natural course of PD [12, 75, 168, 189]. For a
comprehensive account of what is known about the under-
lying cellular and molecular mechanisms of cell-to-cell
transfer of α-syn, we refer readers to other recent review
articles on the topic [190–192] as it is beyond the scope of
the current article. In brief, endocytosis [13, 193, 194] is
strongly implicated as a α-syn uptake mechanism, and exo-
somes have been suggested to play a role when α-syn exits
from cells. It has also been speculated that direct cell-to-cell
transmission of α-syn occurs via tunneling nanotubes (tubes
with a diameter <200 nm and containing F-actin) because a
prior study demonstrated transfer of prion-protein via such
structures [195]. Currently, the evidence linking α-syn mis-
folding or aggregation with cell-to-cell transfer is largely
circumstantial. More studies are required to determine
whether an increase of aggregated α-syn in a model system
leads directly to an increase of the transfer rate of the
protein. These studies are currently ongoing within our
and other laboratories and should provide the evidence
required to validate this hypothesis. Furthermore, the effects
of neuroinflammation on the aforementioned cellular mech-
anisms are not known and inflammation might affect the
rate of cell-to-cell α-syn transfer in either direction. For
example, it is conceivable that some aspects of inflamma-
tion mitigates interneuronal α-syn transfer because activated
microglia may phagocytose extracellular α-syn [44], there-
by reducing the likelihood of neuron-to-neuron transfer of
pathological α-syn. This hypothesis, however, remains to be
tested. On the other hand, it has become clear that exposure
of glial cells to α-syn or uptake of α-syn by astrocytes can
turn their phenotype into a potentially more detrimental one
for neurons [196, 197].
Conclusions and Proposed Hypothesis
Although α-syn aggregation appears to be central to the
development and progression of PD pathology, inflamma-
tion also plays an important role in this disease. Immune
Fig. 3 α-Syn propagates from mouse brain to a graft of dopaminergic
neurons. Confocal planes of a tyrosine hydroxylase-positive mouse
neuron (green, a) transplanted in the striatum of a mouse overexpress-
ing human α-syn. The arrowheads indicate the localization inside the
grafted mouse cell of several human α-syn (red, b) dots, which have
been transferred from the host brain. c An overlay of a and b. Scale bar
5 μm. Figure courtesy of Dr. Elodie Angot
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activation in the GI tract or in the olfactory system via
chemical or virus exposure might trigger α-syn misfolding,
subsequent aggregation, and propagation to the brain. It is
also possible that neuroinflammation promotes the prion-
like transfer of α-syn by increasing its release, increasing its
uptake, or both. However, further studies are needed to
support this hypothesis. If correct, it will open up new
avenues for early detection and therapeutic intervention.
For example, one could speculate that it will be possible to
develop therapies which slow down the progression of PD
by reducing the underlying inflammation and mitigating its
effects on cell-to-cell α-syn transfer. In addition, it is
conceivable that it would be possible to adopt a pre-
ventive strategy and lower the risk of developing PD by
treating the triggers of inflammation in the olfactory or
gastrointestinal system.
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